Early oseltamivir reduces risk for influenza-associated aspergillosis in a double-hit murine model.


Journal

Virulence
ISSN: 2150-5608
Titre abrégé: Virulence
Pays: United States
ID NLM: 101531386

Informations de publication

Date de publication:
12 2021
Historique:
entrez: 21 9 2021
pubmed: 22 9 2021
medline: 16 4 2022
Statut: ppublish

Résumé

Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection occurring mainly in immunocompromised patients. We recently identified IPA as an emerging co-infection with high mortality in critically ill, but otherwise immunocompetent influenza patients. The neuraminidase inhibitor oseltamivir is the current standard-of-care treatment in hospitalized influenza patients; however, its efficacy in influenza-associated pulmonary aspergillosis (IAPA) is not known. Therefore, we have established an imaging-supported double-hit mouse model to investigate the therapeutic effect of oseltamivir on the development of IAPA. Immunocompetent mice received intranasal instillation influenza A or PBS followed by orotracheal inoculation with

Identifiants

pubmed: 34546839
doi: 10.1080/21505594.2021.1974327
pmc: PMC8923074
doi:

Substances chimiques

Oseltamivir 20O93L6F9H

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2493-2508

Références

Sci Rep. 2019 Nov 26;9(1):17598
pubmed: 31772203
J Infect Dis. 1998 Dec;178(6):1750-60
pubmed: 9815229
Front Immunol. 2020 Feb 13;11:117
pubmed: 32117268
Lancet. 2020 Jan 4;395(10217):4-6
pubmed: 31839278
Nat Rev Microbiol. 2014 Apr;12(4):252-62
pubmed: 24590244
Microbes Infect. 2008 Feb;10(2):175-84
pubmed: 18248765
J Antimicrob Chemother. 2016 Dec;71(12):3528-3535
pubmed: 27530755
Infect Immun. 2015 Oct;83(10):3764-70
pubmed: 26216421
Intensive Care Med. 2018 Feb;44(2):257-260
pubmed: 29026934
Platelets. 2015;26(5):495-7
pubmed: 25166956
Curr Opin Infect Dis. 2018 Dec;31(6):471-480
pubmed: 30299367
Front Immunol. 2013 Mar 05;4:56
pubmed: 23467809
Chem Biol. 2014 Jun 19;21(6):719-31
pubmed: 24816227
Front Cell Infect Microbiol. 2017 Sep 26;7:419
pubmed: 29018774
J Crit Care. 2019 Apr;50:59-65
pubmed: 30481669
Life Sci. 2012 Mar 10;90(11-12):440-5
pubmed: 22269828
Antimicrob Agents Chemother. 1994 Feb;38(2):256-9
pubmed: 8192454
Fundam Clin Pharmacol. 2016 Oct;30(5):483-5
pubmed: 27343486
Antiviral Res. 2016 Dec;136:45-50
pubmed: 27771390
Clin Respir J. 2019 Aug;13(8):540-542
pubmed: 31074569
Front Immunol. 2019 Mar 01;10:336
pubmed: 30881357
J Immunol. 2020 Jul 15;205(2):480-488
pubmed: 32522833
Lancet. 2020 Jan 4;395(10217):42-52
pubmed: 31839279
Antimicrob Agents Chemother. 2007 Apr;51(4):1414-24
pubmed: 17296744
Infect Immun. 2001 Mar;69(3):1554-60
pubmed: 11179326
Eukaryot Cell. 2010 Jul;9(7):1120-35
pubmed: 20453072
Dis Model Mech. 2016 Jan;9(1):91-8
pubmed: 26563390
Platelets. 2019;30(6):743-751
pubmed: 30296193
Am J Respir Crit Care Med. 2017 Apr 7;196(4):524-527
pubmed: 28387526
Antivir Ther. 2011;16(2):123-35
pubmed: 21447860
Future Microbiol. 2019 Nov;14:1511-1525
pubmed: 31913059
Lancet Respir Med. 2014 Sep;2(9):750-63
pubmed: 25131494
J Infect Dis. 2003 May 15;187(10):1674; author reply 1674-5
pubmed: 12721949
Lab Invest. 2016 Jun;96(6):692-704
pubmed: 27019389
Intensive Care Med. 2020 Aug;46(8):1524-1535
pubmed: 32572532
Lancet. 2015 May 2;385(9979):1729-1737
pubmed: 25640810
Lancet Respir Med. 2018 Oct;6(10):782-792
pubmed: 30076119
J Immunol. 2014 Apr 1;192(7):3301-7
pubmed: 24563256
Lancet Respir Med. 2014 May;2(5):395-404
pubmed: 24815805
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29760132
J Infect Dis. 2004 Aug 1;190(3):519-26
pubmed: 15243927
Front Med (Lausanne). 2019 May 28;6:109
pubmed: 31192211
Front Immunol. 2018 Mar 16;9:538
pubmed: 29616035
Cell Rep Med. 2021 May 18;2(5):100289
pubmed: 34095887
Eur Respir J. 2015 May;45(5):1463-78
pubmed: 25792631
Nat Med. 2008 May;14(5):558-64
pubmed: 18438414

Auteurs

Laura Seldeslachts (L)

Department of Imaging and Pathology, Biomedical MRI unit/MoSAIC, Ku Leuven, Leuven, Belgium.

Lore Vanderbeke (L)

Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Bacteriology and Mycology, Ku Leuven, Leuven, Belgium.

Astrid Fremau (A)

Department of Imaging and Pathology, Biomedical MRI unit/MoSAIC, Ku Leuven, Leuven, Belgium.

Agustin Reséndiz-Sharpe (A)

Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Bacteriology and Mycology, Ku Leuven, Leuven, Belgium.

Cato Jacobs (C)

Department of Microbiology, Immunology and Transplantation,Laboratory for Clinical Infectious and Inflammatory Disorders, Ku Leuven, Leuven, Belgium.

Bo Laeveren (B)

Department of Imaging and Pathology, Biomedical MRI unit/MoSAIC, Ku Leuven, Leuven, Belgium.

Tessa Ostyn (T)

Department of Imaging and Pathology, Biomedical MRI unit/MoSAIC, Ku Leuven, Leuven, Belgium.

Lieve Naesens (L)

Department of Microbiology, Immunology and Transplantation, Laboratory of Virology and Chemotherapy (Rega Institute), Ku Leuven, Leuven, Belgium.

Matthias Brock (M)

Fungal Biology Group, School of Life Sciences, University of Nottingham, Nottingham, UK.

Frank L Van De Veerdonk (FL)

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands.

Stephanie Humblet-Baron (S)

Department of Microbiology, Immunology and Transplantation, Laboratory of Adaptive Immunity, Ku Leuven, Leuven, Belgium.

Erik Verbeken (E)

Department of Imaging and Pathology, Ku Leuven, Leuven, Belgium.

Katrien Lagrou (K)

Department of Microbiology, Immunology and Transplantation, Laboratory of Clinical Bacteriology and Mycology, Ku Leuven, Leuven, Belgium.

Joost Wauters (J)

Department of Microbiology, Immunology and Transplantation,Laboratory for Clinical Infectious and Inflammatory Disorders, Ku Leuven, Leuven, Belgium.

Greetje Vande Velde (G)

Department of Imaging and Pathology, Biomedical MRI unit/MoSAIC, Ku Leuven, Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH